Overview

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study. The hypothesis for this study is that single oral doses of MK-8266 selected for this study are sufficiently safe and well tolerated by elderly male and elderly female participants with hypertension to permit continued clinical investigation.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.